Mersana Therapeutics/MRSN

$3.52

-6.38%
-
1D1W1MYTD1YMAX

About Mersana Therapeutics

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.

Ticker

MRSN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Martin Huber

Employees

123

Headquarters

Cambridge, United States

MRSN Metrics

BasicAdvanced
$459.74M
Market cap
-
P/E ratio
-$1.50
EPS
1.55
Beta
-
Dividend rate
$459.74M
1.54661
$9.62
$0.80
2.15M
3.364
62.871
68.906
-61.27%
-266.24%
-84.73%
12.474
12.397
12.458
38.65%
31.63%
254.4%

What the Analysts think about MRSN

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 7 analysts.
90.63% upside
High $9.00
Low $5.00
$3.52
Current price
$6.71
Average price target

MRSN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-182.24% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$10.7M
40.79%
Net income
$-19.5M
-53.13%
Profit margin
-182.24%
-66.71%

MRSN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.64%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.52
-$0.47
-$0.35
-$0.16
-
Expected
-$0.44
-$0.44
-$0.36
-$0.16
-$0.18
Surprise
19.33%
6.47%
-3.29%
-2.64%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Mersana Therapeutics stock?

Mersana Therapeutics (MRSN) has a market cap of $459.74M as of April 17, 2024.

What is the P/E ratio for Mersana Therapeutics stock?

The price to earnings (P/E) ratio for Mersana Therapeutics (MRSN) stock is 0 as of April 17, 2024.

Does Mersana Therapeutics stock pay dividends?

No, Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next Mersana Therapeutics dividend payment date?

Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders.

What is the beta indicator for Mersana Therapeutics?

Mersana Therapeutics (MRSN) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Mersana Therapeutics stock price target?

The target price for Mersana Therapeutics (MRSN) stock is $6.71, which is 90.63% above the current price of $3.52. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Mersana Therapeutics stock

Buy or sell Mersana Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing